Exciva
About
Clinical-stage biotech developing therapeutics for neuropsychiatric disorders. Lead program Deraphan targets agitation and aggression in Alzheimer's disease dementia and is in Phase 2/3. Raised EUR 51M Series B in 2026.
Know Exciva?
We list a record's team, investors, portfolio and events once we can verify them. Send us what you know and we'll check it.
Suggest an edit